clinical trial · NCT07252232
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic CancerPDACPDAC - Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal Adenocarcinoma (PDAC)Resected Pancreatic Adenocarcinomadaraxonrasib
brief summary
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
started
Dec 15, 2025
primary completion
May 10, 2029
completion
Jul 10, 2030
last updated
Apr 6, 2026
detailed description
This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve disease-free survival (DFS) compared to SOC observation in patients with resected PDAC who have completed neoadjuvant and/or adjuvant chemotherapy.
official title
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol